Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer

Lung Cancer ◽  
1993 ◽  
Vol 10 (1-2) ◽  
pp. 147-148
2008 ◽  
Vol 26 (26) ◽  
pp. 4347-4352 ◽  
Author(s):  
Christopher S. Lathan ◽  
Bridget A. Neville ◽  
Craig C. Earle

PurposeBlack patients undergo potentially curative surgery for early-stage lung cancer at a lower rate when compared with white patients. Our study examines the relationship between the percentage of black patients treated at a hospital to determine whether it affects the likelihood of obtaining cancer-directed surgery for patients with non–small-cell lung cancer (NSCLC).Patients and MethodsWe examined claims data of Medicare-eligible patients with nonmetastatic NSCLC living in areas monitored by the Surveillance, Epidemiology, and End Results program between 1991 and 2001. Hospitals were categorized by the percentage of black patients seen: ≤ 8%, more than 8% to 29%, and ≥ 30%. Logistic regression with clustering analysis was used to calculate the odds of undergoing surgical resection.ResultsAmong 9,688 patients with NSCLC, 59% of white patients were seen at a hospital that had ≤ 8% black patients, whereas 60% of black patients were seen in hospitals that had ≥ 30% black patients. Regression analysis revealed that hospital racial composition of 30% or greater black patients had a significant negative effect on the likelihood of undergoing surgery for all patients (odds ratio [OR] = 0.71; 95% CI, 0.57 to 0.87), with black race (OR = 0.69; 95% CI, 0.56 to 0.85) and being seen at a low-volume hospital (OR = 0.64; 95% CI, 0.0.49 to 0.83) having a significant negative impact on likelihood of undergoing surgery.ConclusionOur study results indicate that patient and hospital characteristics are significant predictors of undergoing surgery for Medicare beneficiaries with localized lung cancer. Further examination of the role of the patient-, provider-, and hospital-level factors, in association with the decision to pursue surgical treatment of localized lung cancers, is needed.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18064-e18064
Author(s):  
Vinay Nikhil Minocha ◽  
Carmen Smotherman ◽  
Jason Desmond Hew ◽  
Dat C. Pham

e18064 Background: Previous studies have demonstrated disparities in survival outcomes between black and white patients with lung cancer. Black patients are more likely than white patients to have no health insurance or insufficient coverage which may limit their access to treatment. The purpose of this study was to determine the impact of race and insurance status of patients with non-small cell lung cancer on survival outcomes at our institution. Methods: Our study included patients diagnosed and treated for non-small cell lung cancer from 2005 through 2015 at University of Florida hospital in Jacksonville. Cox proportional hazard models were used to study the effect of race (black vs white), insurance, age, tobacco use, family history of cancer and stage on hazard rates for mortality. Time to treatment was compared between blacks and whites using the non-parametric Wilcoxon rank sum test. Results: Of the 1301 patients in our study, 445 (34%) were black. More black patients had Medicaid (24% vs 18%, p = 0.01), and were diagnosed at stage III or IV (81% vs 75%, p = 0.01) compared to white patients. Black patients had higher death rates compared to white patients (80% vs. 71%, p < .0004). Adjusting for stage and insurance, black patients had higher hazard rates for mortality than white patients (HR = 1.18, 95%CI 1.03, 1.35, p = 0.02). Patients with Medicaid and Medicare without supplement had higher hazard rates for mortality compared to other insurance categories (Table). There was no significant difference in time to treatment amongst patients of different races (p = 0.38) and insurance types (p = 0.54). Conclusions: Our study reveals worse survival outcomes in black patients compared to white patients with non-small cell lung cancer, controlling for insurance status and stage at presentation. Future research is needed to determine whether other factors may explain these racial disparities. [Table: see text]


2021 ◽  
Vol 32 ◽  
pp. S334
Author(s):  
Takashi Inoue ◽  
Hiromi Ishihama ◽  
Taimei Tachibana ◽  
Nobuhiro Imamura ◽  
Yuuto Nonaka ◽  
...  

2020 ◽  
pp. 1-7
Author(s):  
David Conde-Estévez ◽  
Inés Monge-Escartín ◽  
Alejandro Ríos-Hoyo ◽  
Xavier Monzonis ◽  
Daniel Echeverría-Esnal ◽  
...  

1990 ◽  
Vol 8 (6) ◽  
pp. 1042-1049 ◽  
Author(s):  
M P Dearing ◽  
S M Steinberg ◽  
R Phelps ◽  
M J Anderson ◽  
J L Mulshine ◽  
...  

In a study of 411 patients with small-cell lung cancer (SCLC) entered on therapeutic clinical trials between 1973 and 1987, we analyzed whether changes in the prognostic importance of pretreatment factors had occurred during the 14-year time period. After adjusting for other prognostic factors, brain involvement was associated with shorter survival in patients treated before December 1979 (P = .024) but not in patients treated thereafter (P = .54). The patients diagnosed before 1979 had brain metastases documented by radionuclide scan while computed cranial tomography (CCT) was more commonly used after 1979. Patients who had brain metastases diagnosed by radionuclide scan lived a shorter period of time than patients who had the diagnosis made by the more sensitive CCT scan (P = .031). In contrast, Cox proportional hazards modeling showed that liver metastases in patients were associated with shorter survival in patients treated after 1979 (P = .0007) but not in patients treated before then (P = .30). A larger proportion of patients had a routine liver biopsy before 1979 than after 1979 when more patients had the liver staged with less sensitive imaging studies and biochemical parameters. Patients with SCLC whose cancer was confined to the thorax but had medical or anatomic contraindications to intensive chest radiotherapy had similar survival compared with patients with limited-stage SCLC who were treated with combination chemotherapy alone (P = .68). From these data we conclude: (1) the sensitivity of the staging procedures used can affect the impact on survival of cancer involvement of a given site; and (2) patients with cancer confined to their chest with medical or anatomic contraindications to chest radiotherapy do not have a shorter survival than patients with limited-stage disease treated with chemotherapy alone.


CHEST Journal ◽  
2002 ◽  
Vol 122 (3) ◽  
pp. 1037-1057 ◽  
Author(s):  
Michael D. Brundage ◽  
Diane Davies ◽  
William J. Mackillop

2000 ◽  
Vol 70 (4) ◽  
pp. 1168-1171 ◽  
Author(s):  
Abdul R Jazieh ◽  
Mohammad Hussain ◽  
John A Howington ◽  
H.J Spencer ◽  
Muhammad Husain ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document